Cambridge Trust’s Myriad Genetics MYGN Stock Holding History

Cambridge Trust’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-155	Closed	-$4K	–	1074
2021 Q4	$4K	Buy	+155	New	+$4.49K	﹤0.01%	908

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Cambridge Trust's MYGN Position: Q1 2022 in Review

Cambridge Trust sold out of Myriad Genetics (MYGN) in Q1 2022, closing a stake of 155 shares — an estimated $4K sold.

Cambridge Trust first reported a position in MYGN in Q4 2021 and held it in 1 quarter. The position peaked at $4K in Q4 2021. 205 funds tracked by Wall St. Rank hold MYGN as of Q1 2022.

Cambridge Trust reported no remaining Myriad Genetics position as of Q1 2022 after selling out during the quarter.
Cambridge Trust sold 155 Myriad Genetics shares in Q1 2022, an estimated $4K.
Cambridge Trust first reported a position in Myriad Genetics in Q4 2021 and held it in 1 quarter.
Cambridge Trust's Myriad Genetics position peaked at $4K in Q4 2021.
205 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2022.

Based on Cambridge Trust's 13F filing for Q1 2022, filed 12 May 2022.